These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 7530697)

  • 21. A rapid bioassay for the determination of non-nucleoside HIV-1 reverse transcriptase inhibitor plasma levels.
    O'Brien JA; Ostovic D; Schorn TW; Smith SJ; Ruffing TL; Siegl PK; Goldman ME
    Life Sci; 1993; 52(3):243-9. PubMed ID: 7678687
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics, safety and tolerability of pirfenidone and its major metabolite after single and multiple oral doses in healthy Chinese subjects under fed conditions.
    Huang NY; Ding L; Wang J; Zhang QY; Liu X; Lin HD; Hua WY
    Drug Res (Stuttg); 2013 Aug; 63(8):388-95. PubMed ID: 23580109
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-performance liquid chromatographic procedure for the determination of a non-nucleoside HIV-1 reverse transcriptase inhibitor in human plasma.
    Woolf E; Matuszewski B
    J Chromatogr; 1992 May; 577(1):129-34. PubMed ID: 1383249
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single-dose escalation and multiple-dose safety, tolerability, and pharmacokinetics of IDX899, a candidate human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor, in healthy subjects.
    Zhou XJ; Pietropaolo K; Damphousse D; Belanger B; Chen J; Sullivan-Bólyai J; Mayers D
    Antimicrob Agents Chemother; 2009 May; 53(5):1739-46. PubMed ID: 19223643
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety, tolerability, and pharmacokinetics of SMT C1100, a 2-arylbenzoxazole utrophin modulator, following single- and multiple-dose administration to healthy male adult volunteers.
    Tinsley J; Robinson N; Davies KE
    J Clin Pharmacol; 2015 Jun; 55(6):698-707. PubMed ID: 25651188
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Column-switching high-performance liquid chromatographic determination of a 2-pyridinone-based human immunodeficiency virus type 1 (HIV-1)-specific reverse transcriptase inhibitor in human plasma.
    Woolf EJ; Matuszewski BK
    Pharm Res; 1993 Jan; 10(1):56-60. PubMed ID: 7679213
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-performance liquid chromatographic method for the determination of an HIV-1 non-nucleoside reverse transcriptase inhibitor (L-696,229) in plasma samples from animals.
    Lee LL; Herold ML; Zacchei AG
    J Chromatogr B Biomed Appl; 1996 Oct; 685(2):323-8. PubMed ID: 8953174
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and tolerability of GW420867X, a nonnucleoside reverse transcriptase inhibitor, following single escalating doses in healthy male volunteers.
    Moore KH; Cass LM; Dallow N; Hardman TC; Jones A; Boyce M; Prince WT
    J Clin Pharmacol; 2001 Oct; 41(10):1098-105. PubMed ID: 11583478
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Possible toxicity associated with L-697,661 administration in a patient with AIDS.
    Harris PJ
    AIDS; 1992 Jun; 6(6):597-9. PubMed ID: 1382453
    [No Abstract]   [Full Text] [Related]  

  • 30. Safety, tolerability, and pharmacokinetics of single oral doses of BCH-10652 in healthy adult males.
    Smith PF; Forrest A; Ballow CH; Martin DE; Proulx L
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2816-23. PubMed ID: 10991865
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simultaneous determination of L-702,007, a HIV-1 reverse transcriptase inhibitor, and its 6-hydroxy metabolite in human plasma by column-switching high-performance liquid chromatography with fluorescence detection.
    Woolf EJ; Matuszewski B
    J Chromatogr A; 1996 Apr; 729(1-2):211-7. PubMed ID: 9004942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics, safety and tolerability of long-acting parenteral intramuscular injection formulations of doravirine.
    Yee KL; Mittal S; Fan L; Triantafyllou I; Dockendorf MF; Fackler PH; Stoch SA; Khalilieh SG; Iwamoto M
    J Clin Pharm Ther; 2020 Oct; 45(5):1098-1105. PubMed ID: 32501541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of representative 3-hydroxypyridin-4-ones in rabbits: CP20 and CP94.
    Fredenburg AM; Wedlund PJ; Skinner TL; Damani LA; Hider RC; Yokel RA
    Drug Metab Dispos; 1993; 21(2):255-8. PubMed ID: 8097694
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolism and pharmacokinetics of 1-(2'-hydroxy-ethyl)- and 1-(3'-hydroxypropyl)-2-ethyl-3-hydroxypyridin-4-ones in the rat.
    Singh S; Choudhury R; Epemolu RO; Hider RC
    Eur J Drug Metab Pharmacokinet; 1996; 21(1):33-41. PubMed ID: 8839676
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group.
    Saag MS; Emini EA; Laskin OL; Douglas J; Lapidus WI; Schleif WA; Whitley RJ; Hildebrand C; Byrnes VW; Kappes JC
    N Engl J Med; 1993 Oct; 329(15):1065-72. PubMed ID: 7690462
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolism of 3-[2-(benzoxazol-2-yl)ethyl]-5-ethyl-6-methylpyridin-2 (1H)-one (L-696,229), an HIV-1 reverse transcriptase inhibitor, by rat liver slices and in humans.
    Balani SK; Kauffman LR; Arison BH; Olah TV; Goldman ME; Varga SL; O'Brien JA; Ramjit HG; Rooney CS; Hoffman JM
    Drug Metab Dispos; 1994; 22(2):200-5. PubMed ID: 7516852
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects.
    Anderson MS; Gilmartin J; Cilissen C; De Lepeleire I; Van Bortel L; Dockendorf MF; Tetteh E; Ancona JK; Liu R; Guo Y; Wagner JA; Butterton JR
    Antivir Ther; 2015; 20(4):397-405. PubMed ID: 25470746
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human pharmacokinetics and tolerability of L-697,639, a non-nucleoside HIV-1 reverse transcriptase inhibitor.
    Van Hecken A; Depre M; De Lepeleire I; Laskin O; Au T; Woolf E; Yeh KC; De Schepper PJ
    Int J Clin Pharmacol Res; 1994; 14(2):45-50. PubMed ID: 7530697
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.